Elevated lipoprotein(a) is associated with increased inflammatory and myocardial injury markers in acute coronary syndrome patients undergoing percutaneous coronary intervention
The results indicate that elevated Lp(a) is associated with increased atherothrombotic burden in coronary syndrome, and a significant positive correlations between Lp(a) and both hsCRP and hsTroponin T were found.
Abstract
Lipoprotein(a) [Lp(a)] is recognized as an independent cardiovascular (CV) risk factor, with the ESC defining high risk at ›105 nmol/L. While Lp(a) is genetically determined and considered stable over time, its interaction with acute inflammatory responses and myocardial injury during acute coronary syndrome (ACS) has not been fully elucidated.
To investigate associations between Lp(a), demographic characteristics, risk factors, and biomarkers of myocardial necrosis in patients undergoing percutaneous coronary intervention (PCI) for ACS.
We determined Lp(a) levels, clinical and laboratory parameters in patients admitted to our institution over 18 months for ACS with PCI (n=281, STEMI: 154, NSTEMI: 75, UAP: 52).
Lp(a) showed non-normal distribution with median 20.8 nmol/L (IQR: 8.7-80.6). Sixty patients (21%) were in the high CV risk group based on ESC Lp(a) criteria. Patients were divided into quartiles based on Lp(a) levels (Q1 median: 7.0 nmol/L [IQR: 7.0-7.3] vs. Q4 median: 162.7 nmol/L [IQR: 113-213]). No significant differences were found in demographic parameters (hypertension, diabetes, smoking, prior ACS and stroke, statin use; p›0.05). Female sex showed a trend toward higher Lp(a) (p=0.1). Importantly, patient age did not differ significantly between the lowest and highest Lp(a) quartiles (Q1 median: 55 years [IQR: 48-67] vs. Q4 median: 58 years [IQR: 50-68], p=0.26). Both pre- and post-PCI hsTroponin T levels were significantly higher in the highest Lp(a) quartile (pre-PCI hsTroponin T: Q1 median: 146 ng/L [IQR: 27-797] vs. Q4 median: 580 ng/L [IQR: 111- 1288], p=0.015; post-PCI hsTroponin T: Q1 median: 279 ng/L [IQR: 70-1261] vs. Q4 median: 944 ng/L [IQR: 288-3215], p=0.016). Significant positive correlations were found between Lp(a) and both pre-PCI hsTroponin T (ρ=0.15, p‹0.05) and post-PCI hsTroponin T in the total population (ρ=0.17, p‹0.05). Similarly, hsCRP was significantly higher in the highest Lp(a) quartile (Q1 median: 3.66 mg/L [IQR: 1.33-9.4] vs. Q4 median: 9.2 mg/L [IQR: 3.7-37.8], p=0.0001), and a significant positive correlation was detected between Lp(a) and hsCRP (ρ=0.24, p‹0.05).
Twenty-one percent of ACS patients undergoing PCI in our cohort had Lp(a) levels exceeding the ESC-recommended high cardiovascular risk threshold. Significantly higher pre- and post-PCI hsTroponin and hsCRP levels were observed in patients with elevated Lp(a) in the upper quartile. These findings were corroborated by significant positive correlations between Lp(a) and both hsCRP and hsTroponin biomarkers. Our results indicate that elevated Lp(a) is associated with increased atherothrombotic and inflammatory burden in acute coronary syndrome, suggesting a potential role for Lp(a) assessment in risk stratification during the acute phase.
Elevated Lp(a) is independently associated with adverse cardiovascular outcomes after AMI, particularly HF, and measurement of Lp(a) may improve risk stratification after AMI and help identify patients at high risk of developing HF, including HFpEF.
Yang Wang, T. Ueda, A. Okamura et al.· Circulation Journal· 0 citations
BACKGROUND
Hypercholesterolemia adversely affects ischemia-reperfusion injury in acute ST-elevation myocardial infarction (STEMI). Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor beyond traditional lipid markers; however, its impact on ischemic myocardial injury remains unclear. We therefore investi...
M. Holzknecht, C. Tiller, I. Lechner et al.· Clinical Research in Cardiol...· 0 citations
A clear dose–response relationship was observed, with progressively higher odds of multivessel CAD across increasing Lp(a) quartiles, underscoring the contribution of Lp(a) to residual atherosclerotic risk beyond traditional cardiometabolic factors.
P. Theofilis, P. Vlachakis, A. Papanikolaou et al.· European Heart Journal· 0 citations
In ACS patients, the predictive value of lipid biomarkers for disease severity is fundamentally modified by prior LLT, and in patients on prior LLT, Lp(a) emerged as a strong independent predictor of severe ASCVD, whereas lower apoB levels were paradoxically associated with higher disease burden, likely reflecting more...
A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al.· European Heart Journal· 0 citations
Lp(a) shows a transient, non-linear increase during the acute phase of ACS associated with inflammatory response, and early post-ACS Lp(a) measurements may not reflect steady-state levels and should be interpreted cautiously.
S. Fujioka, K. Sakaguchi, H. Kusumoto et al.· European Heart Journal· 0 citations
Young women presenting with acute coronary syndrome (ACS) represent a distinct clinical phenotype with heterogeneous mechanisms: premature atherosclerosis and non-obstructive coronary disease. In the WAMIF study (Women with Acute Myocardial Infarction), a French national multicenter cohort of women under 50 years...
S. Manzo-Silberman, A. Bellemain-Appaix, R. Khani-Bittar et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.